BDBeyza Doğan

Beyza Doğan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beyza Doğan has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unexpected finding of AA amyloidosis with novel genetic variants in the MEFV gene in patients undergoing kidney biopsy for proteinuria. A case series.

    by Beyza Doğan, Süleyman Karaköse, Edip Erkuş, İbRahim Güney

    Amyloidosis is a systemic clinical condition characterised by the extracellular deposition of misfolded proteins in various organs, most frequently involving the heart, kidneys, gastrointestinal tract, and bone marrow. Among its types, AA amyloidosis accounts for approximately 15% of cases and is mainly secondary to chronic infectious or inflammatory conditions. The association between Familial Mediterranean Fever (FMF) and AA amyloidosis is well-established, with the MEFV gene’s M694V mutation being the most recognised risk factor. However, the role of other genetic variants often remains underestimated. This case series presents a spectrum of AA amyloidosis patients harbouring various MEFV gene variants. By emphasizing the clinical presentations and diagnostic challenges encountered, this report aims to highlight the clinical significance of heterozygous and less common variants that are frequently overlooked in the progression to AA amyloidosis.

  • Open Access

    Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort

    by Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlKer Atay, et al.

    Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are scarce. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome was hyperkalemia risk signal (potassium ≥5.0 mEq/l), and the secondary outcome was clinically meaningful hyperkalemia (potassium ≥5.5 mEq/l) within 3 months. Multivariate logistic regression (LR) was used to define features associated with the both outcomes. Machine learning methods of LR, random forest (RF), extreme gradient boosting, and categorical boosting classifiers were used to define important features associated with the primary outcome. Results: Total 699 patients were included. Of them, 259 (37.1%) reached the primary outcome, and 51 (7.3%) reached the secondary outcome. Baseline serum potassium, estimated glomerular filtration rate (eGFR), and finerenone dose were associated with the both outcomes in multivariate LR. Machine learning analyses consistently identified baseline serum potassium and eGFR as the most influential factors associated with primary outcome, with thiazide use being associated with lower risk and 20 mg (compared to 10 mg) finerenone initiation being associated with higher risk. LR demonstrated the highest recall; RF achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.

  • Open Access

    Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort

    by Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.


  • Open Access

    Effect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment

    by Fatih Ergül, Beyza Doğan, Mikail Dağ, Süleyman Karaköse, İbRahim Güney

    Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.

  • Open Access

    The Relationship Between Mucociliary Clearance Time and Peritonitis Frequency in Patients Receiving Peritoneal Dialysis

    by Beyza Doğan, Fatih Ergül, Ramazan Basut, Süleyman Karaköse, Abitter Yücel, Mikail Dağ, İbRahim Güney

    Background: The present study sought to explore the association between nasal mucociliary clearance time (MCT) and the frequency of peritonitis among patients with chronic kidney disease (CKD) treated by peritoneal dialysis (PD). Methods: This cross-sectional study enrolled 24 patients with CKD treated by PD and 24 healthy volunteers. Nasal muco ciliary function was assessed using the saccharin transit time test. In this procedure, a saccharin particle with a 1 mm diameter was meticulously placed on the anteromedial surface of the inferior nasal concha. The 2 groups were compared based on their mean MCT. Within the patient group, the number of peritonitis cases in the last year was evaluated, and the correlation between MCT and the occurrence of peritonitis was analyzed. Results: The patient group consisted of 15 females and 9 males, with a mean age of 52.6 years. The control group included 14 females and 10 males, with a mean age of 47.5 years. The mean duration of PD among the followed cohort was 20 months, ranging from 3 to 190 months. The comparison of mean MCT between patients with a history of peritonitis and those with out peritonitis did not reveal a statistically significant difference (P = .333). However, the neutrophil-to-lymphocyte ratio was significantly elevated in the group exhibiting prolonged MCT (P = .046). Conclusion: Although this study found no statistically significant direct relationship between peritonitis incidence and MCT, the research aimed to evaluate MCT as a potential indicator of susceptibility to respiratory tract infections, which play a role in the development of peritonitis. Cite this article as: Doğan B, Ergül F, Basut R, et al. The relationship between mucociliary clearance time and peritonitis frequency in patients receiving peritoneal dialysis. Turk J Nephrol. 2026;35(1):67-71.

  • Open Access

    The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease

    by Süleyman Karaköse, Beyza Doğan, Fatih Ergül, İbRahim Güney

    SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.

  • Effects of central obesity and pancreatic adiposity on beta-cell function in patients with newly diagnosed type 2 diabetes mellitus

    by Beyza Doğan, Mevlüt Hakan Göktepe, Hilal Akay Çizmecioğlu, Cengiz Kadıyoran, İbRahim Güney

  • Assessing ciliary function in polycystic kidney disease: beyond the kidney

    by Beyza Doğan, Fatih Ergül, Mikail Dağ, Süleyman Karaköse, Latif Emre Özdemir, Abitter Yücel, İbRahim Güney

    This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance. The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups. In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001). This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.